Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$5.52	$4.78	$1.58 ▼ $7.27	$492.06M	-0.59	1.20 million shs	890,299 shs
ATYR Atyr PHARMA	$5.20 -4.2%	$3.75	$1.42 ▼ $5.98	$462.82M	0.88	1.04 million shs	2.11 million shs
PLX Protalix BioTherapeutics	$1.49 -3.2%	$2.13	$0.82 ▼ $3.10	$118.61M	-0.21	557,304 shs	500,745 shs
TRML Tourmaline Bio	$19.68 -1.1%	$16.23	$11.56 ▼ $29.79	$505.48M	2.05	274,816 shs	154,595 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	0.00%	+3.56%	+26.90%	+52.07%	+222.81%
ATYR Atyr PHARMA	-4.24%	-3.35%	+71.62%	+30.98%	+519,999,900.00%
PLX Protalix BioTherapeutics	-3.25%	-5.70%	-10.78%	-33.48%	+25.74%
TRML Tourmaline Bio	-1.11%	+2.13%	+26.97%	+4.68%	+21.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMLX Amylyx Pharmaceuticals	4.1373 of 5 stars	4.6	3.0	2.0	4.2	1.3
ATYR Atyr PHARMA	3.0262 of 5 stars	3.6	1.0	4.0	3.3	0.6
PLX Protalix BioTherapeutics	2.5918 of 5 stars	3.5	4.0	0.6	0.0	1.9
TRML Tourmaline Bio	2.8433 of 5 stars	3.5	3.0	3.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.11	Buy	$9.83	78.14% Upside
ATYR Atyr PHARMA	3.14	Buy	$18.60	257.69% Upside
PLX Protalix BioTherapeutics	3.00	Buy	$15.00	906.71% Upside
TRML Tourmaline Bio	3.00	Buy	$49.33	150.68% Upside

Current Analyst Ratings Breakdown

Latest PLX, ATYR, TRML, and AMLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/4/2025	ATYR Atyr PHARMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
5/30/2025	AMLX Amylyx Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/19/2025	ATYR Atyr PHARMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
5/14/2025	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$7.00 ➝ $8.00
5/9/2025	AMLX Amylyx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $16.00
5/7/2025	AMLX Amylyx Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $10.00
5/6/2025	AMLX Amylyx Pharmaceuticals	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/5/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
5/5/2025	TRML Tourmaline Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
4/23/2025	TRML Tourmaline Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$70.00
4/7/2025	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$3.00 ➝ $7.00

(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	-$1.27M	-386.84	$1.00 per share	5.51	$6.42 per share	0.86
ATYR Atyr PHARMA	$235K	1,969.45	N/A	N/A	$1.54 per share	3.38
PLX Protalix BioTherapeutics	$59.76M	1.98	$0.08 per share	17.80	$0.47 per share	3.17
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	$10.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	$49.27M	-$3.11	N/A	N/A	N/A	N/A	-36.97%	-29.61%	8/6/2025 (Estimated)
ATYR Atyr PHARMA	-$50.39M	-$0.81	N/A	N/A	N/A	N/A	-79.44%	-59.16%	8/12/2025 (Estimated)
PLX Protalix BioTherapeutics	$8.31M	$0.04	N/A	4.81	N/A	-21.03%	-30.89%	-11.74%	N/A
TRML Tourmaline Bio	-$42.12M	-$3.21	N/A	N/A	N/A	N/A	-20.97%	-20.56%	8/6/2025 (Estimated)

Latest PLX, ATYR, TRML, and AMLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2025	Q1	PLX Protalix BioTherapeutics	N/A	-$0.05	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	AMLX Amylyx Pharmaceuticals	-$0.45	-$0.42	+$0.03	-$0.42	N/A	N/A
5/7/2025	Q1 2025	ATYR Atyr PHARMA	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A
5/2/2025	Q1 2025	TRML Tourmaline Bio	-$0.91	-$0.89	+$0.02	-$0.89	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	$1.02	18.41%	N/A	N/A	N/A
ATYR Atyr PHARMA	N/A	N/A	N/A	N/A	N/A
PLX Protalix BioTherapeutics	N/A	N/A	N/A	N/A	N/A
TRML Tourmaline Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	4.55	4.55
ATYR Atyr PHARMA	0.02	5.41	5.41
PLX Protalix BioTherapeutics	N/A	1.98	1.27
TRML Tourmaline Bio	N/A	40.33	40.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
ATYR Atyr PHARMA	61.72%
PLX Protalix BioTherapeutics	16.53%
TRML Tourmaline Bio	91.89%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	11.70%
ATYR Atyr PHARMA	3.70%
PLX Protalix BioTherapeutics	6.50%
TRML Tourmaline Bio	13.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	200	89.14 million	60.53 million	Optionable
ATYR Atyr PHARMA	53	89.00 million	80.84 million	Optionable
PLX Protalix BioTherapeutics	200	79.61 million	69.00 million	Optionable
TRML Tourmaline Bio	44	25.69 million	22.82 million	Optionable

PLX, ATYR, TRML, and AMLX Headlines

Recent News About These Companies

Cantor Fitzgerald Weighs in on Tourmaline Bio FY2026 Earnings

June 11 at 8:45 AM | marketbeat.com

Two Sigma Investments LP Sells 21,904 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)

June 10, 2025 | marketbeat.com

Tourmaline Bio Elects Directors and Ratifies Auditor

June 6, 2025 | tipranks.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Shares Bought by Bank of America Corp DE

June 6, 2025 | marketbeat.com

Tourmaline Bio (NASDAQ:TRML) Trading Up 7.2% - Here's What Happened

June 5, 2025 | marketbeat.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of "Buy" from Brokerages

May 31, 2025 | marketbeat.com

H.C. Wainwright maintains $50 target on Tourmaline Bio stock

May 29, 2025 | uk.investing.com

H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results

May 29, 2025 | msn.com

Millennium Management LLC Has $7.40 Million Position in Tourmaline Bio, Inc. (NASDAQ:TRML)

May 28, 2025 | marketbeat.com

Leerink Partnrs Comments on Tourmaline Bio FY2026 Earnings

May 27, 2025 | marketbeat.com

29,844 Shares in Tourmaline Bio, Inc. (NASDAQ:TRML) Purchased by Rafferty Asset Management LLC

May 25, 2025 | marketbeat.com

BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML)

May 23, 2025 | msn.com

Wexford Capital LP Purchases New Position in Tourmaline Bio, Inc. (NASDAQ:TRML)

May 22, 2025 | marketbeat.com

Tourmaline shares waver as investors mull mid-stage pacibekitug data

May 21, 2025 | thepharmaletter.com

Tourmaline Bio, Inc. (NASDAQ:TRML) Stake Increased by Velan Capital Investment Management LP

May 21, 2025 | marketbeat.com

Tourmaline touts cardiovascular potential of former Pfizer antibody after phase 2 kidney disease win

May 21, 2025 | fiercebiotech.com

Tourmaline Bio posts mid-stage data for anti-inflammatory agent

May 21, 2025 | msn.com

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition

May 20, 2025 | seekingalpha.com

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025

May 19, 2025 | globenewswire.com

Tourmaline Bio Reports Q1 2025 Financial Results

May 7, 2025 | tipranks.com

Why Tourmaline Bio, Inc.’s (TRML) Stock Is Down 7.00%

May 3, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLX, ATYR, TRML, and AMLX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$5.52 0.00 (0.00%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$5.51 -0.01 (-0.18%)

As of 06/13/2025 07:15 PM Eastern

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Atyr PHARMA NASDAQ:ATYR

$5.20 -0.23 (-4.24%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$5.22 +0.01 (+0.29%)

As of 06/13/2025 07:56 PM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Protalix BioTherapeutics NYSE:PLX

$1.49 -0.05 (-3.25%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.51 +0.02 (+1.34%)

As of 06/13/2025 07:51 PM Eastern

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

Tourmaline Bio NASDAQ:TRML

$19.68 -0.22 (-1.11%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$19.68 +0.00 (+0.03%)

As of 06/13/2025 04:25 PM Eastern

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time